CLGN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Collplant Biotechnologies Ltd · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.27 USD
-13.3% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -56.2% below the Trend Line and sits at 0.1% of its 52-week range. The latest completed week returned -13.3%, after a -19.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 80/100 conviction, while the latest news-sentiment score is 46/100. Near-term considerations: volume confirmation is below normal; earnings are due in 17d.

Setup score 19 out of 100
Latest Close 0.27 USD 31 Jul 2026
1W Return -13.3% latest completed week
4W Return -19.8% short-term follow-through
12W Return -32.2% quarterly tape
Trend Breadth 9.6% 5 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 34.89% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -13.3% Latest completed week; four-week move -19.8%. Indicator stack 5/68 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 34.89% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 80/100 conviction; expected move 1416.8%. News sentiment 46/100 56 relevant articles in the latest sentiment read. Event risk 17d Next report is scheduled for 19 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -56.2% below the Trend Line and sits at 0.1% of its 52-week range. The latest completed week returned -13.3%, after a -19.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1112-week average 0.13

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.11Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -19.8% over four weeks, -32.2% over 12 weeks, and -88.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-13.3%
4W-19.8%
12W-32.2%
26W-85.6%
52W-88.1%
Active trend streak0 weeks
Active weeks in one year5
Trend breadth9.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.31Latest activity-pressure read.
Pressure change150.5%Four-week change in activity pressure.
Leadership-81.69Latest relative-leadership reading.
RS change-1.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength66/100Blend of value, momentum, and quality. Underlying universe rank 35; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum58/100Medium-term price momentum. Underlying universe rank 43; rank 1 is best.
Growth58/100Revenue and earnings growth. Underlying universe rank 43; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
15.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-266.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-319.3%
Gross profit retained from each unit of revenue.
Operating margin
-3318.3%
Operating profit retained from revenue.
Free-cash-flow margin
-2969.1%
Free cash flow generated from revenue.
Return on invested capital
-295.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-84.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-52.1%
Net share repurchases relative to market value.
Shareholder yield
-52.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

CLGN shows volatility options pressure with a 80/100 conviction score, put-call volume ratio of 94.00, expected move of 1416.8%, and Sharemaestro trend signal inactive.

Conviction80/100
Expected move1416.8%
Put/call volume94.00
Pressure-93
Speculation64
Volatility96
Trend agreement67
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment46/100

Weighted news tone is neutral across 56 relevant articles.

7 positive · 36 neutral · 13 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings17dNext report is scheduled for 19 Aug 2026; event risk rises as the date approaches.
Options expected move1416.8%Nearest-chain priced movement where available.
52-week drawdown-91.6%Distance below the 52-week high.
13-week volatility6.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher7 of 2619 weeks finished lower.
Best week+16.5%Week of 24 Apr.
Worst week-57.7%Week of 6 Feb.
Latest week-13.3%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains2
Flat weeks0
Modest losses6
Sharp losses13
Recent vol6.4%13-week weekly-return volatility.
Base vol13.0%52-week weekly-return volatility.
Up/down split16/36Count of positive and negative weeks in the 52-week window.
Average skew9.6% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 0/12.

Activity pressure 0.11; No reversal markers Next-Week ExpectancyNegative 34.89%

Next-week expectancy is negative with a 34.89% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 97 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options62/100

CLGN shows volatility options pressure with a 80/100 conviction score, put-call volume ratio of 94.00, expected move of 1416.8%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 1416.8% Sentiment46/100

Weighted news tone is neutral across 56 relevant articles.

CLGN|Collplant Biotechnologies Ltd|Price:0.328|Chg%:+0.001 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings17d

Next report is scheduled for 19 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.27 USD-13.3%0.62 USD3.42 USD0.31-81.69138.9KOff
24 Jul 20260.31 USD-6.0%0.66 USD3.46 USD0.35-79.4483.0KOff
17 Jul 20260.34 USD-9.0%0.70 USD3.49 USD0.21-79.1287.2KOff
10 Jul 20260.37 USD8.2%0.74 USD3.53 USD0.15-78.58217.3KOff
3 Jul 20260.34 USD2.3%0.79 USD3.57 USD0.12-80.18256.1KOff
26 Jun 20260.33 USD-1.3%0.85 USD3.62 USD0.20-80.76154.6KOff
19 Jun 20260.34 USD-0.6%0.91 USD3.67 USD0.31-81.68492.2KOff
12 Jun 20260.34 USD-8.6%0.97 USD3.72 USD0.27-81.42625.3KOff
5 Jun 20260.37 USD-7.7%1.03 USD3.77 USD0.19-79.55304.5KOff
29 May 20260.40 USD-5.7%1.08 USD3.81 USD-0.10-79.32242.3KOff
22 May 20260.43 USD-3.0%1.14 USD3.86 USD-0.36-78.32109.0KOff
15 May 20260.44 USD9.3%1.20 USD3.90 USD-0.53-77.86214.5KOff
8 May 20260.40 USD-2.1%1.26 USD3.94 USD-0.67-80.19180.7KOff
1 May 20260.41 USD-1.3%1.32 USD3.98 USD-0.70-79.11731.1KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.